Email this article 
The effectiveness of intranasal corticosteroids and antihistamines combination - mometasone furoate and azelastine hydrochloride nasal spray in adults with seasonal allergic rhinitis (The results of clinical trial)
- Authors: Nenasheva NM1, Ilina NI2, Fedoskova TG2
-
Affiliations:
- Russian Medical Academy for Postgraduate Education
- Institute of Immunology
- Issue: Vol 13, No 2 (2016)
- Pages: 54-64
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/403
- DOI: https://doi.org/10.36691/RJA403
- ID: 403
Cite item
Open Access
Access granted
Abstract
Background. Intranasal corticosteroids and antihistamines are the basis of pharmacotherapy of allergic rhinitis (AR). The aim of this study was to evaluate the efficacy, safety and tolerability of Momat Rhino Advance (fixed combination of azelastine hydrochloride 140 mcg + mometasone furoate 50 mcg) intranasal spray in seasonal rhinitis patients. Materials and methods. Momat Rhino Advance was administered within 14 days in adults with seasonal AR in comparison with the original azelastine hydrochloride and mometasone furoate, used in combination with each other from separate devices against nasal (TNSS) and non-nasal (TNNSS) rhinitis symptoms. In total, 220 patients 18-65 years old with moderate/severe seasonal AR, were randomized in an open, parallel-group, multicenter clinical trial conducted in 16 centers in the Russian Federation during the period from April to September 2014. Results and conclusion. As a result of the study a marked decreasing of nasal symptoms using scale TNSS (in 89,6% relatively to the initial visit, p<0,05), and non-nasal symptoms using scale TNNSS (in 92,8% relatively to the initial visit, p<0,05) was obtained. Quality of life index using a standardized questionnaire RQLQ, showed a significant positive trend in treated patients with AR (p<0,05). There were no differences between the main group and other groups of patients in relation to nasal and other symptoms of seasonal AR and quality of life index. All studied drugs have shown high level of safety and tolerability. Thus, there was no difference between Momat Rhino Advance (fixed combination of azelastine hydrochloride 140 mcg + mometasone furoate 50 mcg, Glenmark Pharmaceuticals Ltd., India) nasal spray efficacy and safety in comparison with azelastine hydrochloride - nasal spray, and mometasone furoate nasal spray, applied from the individual devices in seasonal allergic rhinitis patients. The optimum regimen of using of Momat Rhino Advance was twice daily.
Full Text
About the authors
N M Nenasheva
Russian Medical Academy for Postgraduate Education
Email: 1444031@gmail.com
N I Ilina
Institute of Immunology
T G Fedoskova
Institute of Immunology
References
- Bousquet J., Khaltaev N., Cruz A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2008, v. 63, p. 1-160.
- Chuchalin A., Khaltaev N., Antonov N. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of COPD. 2014, v. 9, p. 963-974.
- Ильина Н.И. Аллергический ринит. Consilium medicum. 2000, № 8, с. 338-344.
- Федоскова Т.Г Особенности ведения больных круглогодичным ринитом при острых респираторных инфекциях. Рус. мед. журн. 2011, № 8, с. 518-521.
- Horak F. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Therapeutics and Clinical Risk Management. 2008, v. 4, p. 1009-1022.
- Juniper E.F., Guyatt G.H., Griffith L.E., Ferrie P.J. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J. Allergy Clin. Immunol. 1996, v. 98, p. 843-845.
- Bernstein J.A. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr. Med. Res. Opin. 2007, v. 23, p. 2441-2452.
- Lee C., Corren J. Review of azelastatine nasal spray in the treatment of allergic and non-allergic rhinitis. Expert Opin. Pharmacoter. 2007, v. 8, p. 701-709.
- Portnoy J., Van Osdol T., Williams P. Evidence-based strategies for treatment of alergic rhinitis. Curr. Allergy Asthma Rep. 2004, v. 4, р. 439-446.
- Lamb C.E., Ratner P.H., Johnson C.E. et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr. Med. Res. Opin. 2006, v. 22, p. 1203-1210.
- Meltzer E.O., Blaiss M.S., Derebery M.J. et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J. Allergy Clin. Immunol. 2009, v. 124, p. 43-70.
- Carr W., Bernstein J., Lieberman P. et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 2012, v. 129, p. 1282-1289.
- Инструкция по применению лекарственного препарата Момат Рино Адванс.
Supplementary files
